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A B S T R A C T
Purpose: To investigate whether planning of pregnancy in women with epilepsy affects seizure control
during pregnancy and to compare the maternal and neonatal outcomes in planned and unplanned
pregnancies.
Methods: This was a retrospective cohort study of 153 pregnant women with epilepsy who were treated
at the University of Tsukuba Hospital and Hokkaido University Hospital between 2003 and 2011.
Twenty-one pregnancies were excluded due to insufﬁcient data. Data of patients followed by
neurologists during their planned pregnancies (planned-pregnancy group, n = 51) were compared to
those of patients referred to neurologists after conception for managing epilepsy during pregnancy
(unplanned-pregnancy group, n = 81). The treatment proﬁle for epilepsy, seizure control, and maternal
and neonatal outcomes in both groups were compared using Chi-square test or Fisher’s exact test and
Mann–Whitney U test.
Results: Compared to the unplanned-pregnancy group, the planned-pregnancy group showed a
signiﬁcantly greater proportion of patients receiving monotherapy with antiepileptic drugs (80% vs. 61%:
planned vs. unplanned, P = 0.049) and those not requiring valproic acid (77% vs. 56%, P = 0.031).
Furthermore, the frequency of epileptic seizures (16% vs. 35%, P = 0.018) and changes in antiepileptic
drugs (24% vs. 41%, P = 0.042) were signiﬁcantly lower in the planned-pregnancy group than in the
unplanned-pregnancy group. No signiﬁcant intergroup differences were noted in the obstetric
complications and neonatal outcomes, including congenital malformations.
Conclusion: For women with epilepsy, planning of pregnancy is associated with good seizure control
during pregnancy and less fetal exposure to antiepileptic drugs.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Population-based studies indicate that the prevalence of
epilepsy in pregnant women is 0.7%, whereas registry-based
studies suggest a range of 0.2–0.4%.1 Thus, obstetricians often
encounter cases of pregnancy in women with epilepsy (WWE) andAbbreviations: WWE, women with epilepsy; AED, antiepileptic drug; MCM, major
congenital malformation; VPA, valproic acid; PB, phenobarbital; CBZ, carbamaze-
pine; PHT, phenytoin; VSD, ventricular septal defect.
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http://dx.doi.org/10.1016/j.seizure.2013.10.003can be involved in the management of the pregnancies in these
women as well as offer preconception counseling. In general,
although the pregnancy outcomes in most WWE are favorable,
epilepsy poses additional risks for the mother and fetus, including
the potential effects of teratogenic antiepileptic drugs (AEDs), the
effects of maternal seizures on the fetus, and genetic risks, all of
which contribute to a two- to three-fold increase in the risk of
adverse outcomes.2 These adverse outcomes include major
congenital malformation (MCM) in the fetus and long-term
developmental delay.
A maternal seizure can directly affect the fetus and cause fetal
hypoxia and distress. Additionally, adverse effects on the mother
include falls; superﬁcial abdominal hematomas; burns or other
accidents; and signiﬁcant obstetric sequelae, such as placental
abruption and premature labor and delivery. Various complica-
tions of pregnancy have been reported in WWE. These women are
at an increased risk of spontaneous abortion, induction of labor,vier Ltd. All rights reserved.
Table 1
Maternal characteristics.
Planned Unplanned P-Value
Number 51 81
Age 17–42 22–38 0.012a
Nullgravida 20 (39.2%) 37 (45.7%) 0.47
Nullipara 29 (56.9%) 53 (65.4%) 0.32
BMI 16.9–38.3 14.3–32.8 0.15
Japanese 49 (96.1%) 79 (97.5%) 0.64
On welfare 1 (2.0%) 4 (4.9%) 0.65
a P < 0.05, BMI: body mass index.
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exposed to AEDs in utero are at a high risk of fetal growth
restriction, preterm birth, low birth weight, and low Apgar scores.3
The incidence of fetal MCM in women without epilepsy is 1.6–
2.2%,4–6 whereas that in WWE is higher, at 2.8–3.6%7–9 who take
AEDs and at 4.2–6.7% who do not take AEDs.4,5,7–9 Furthermore, the
risk of fetal MCM increases with the number of AEDs adminis-
tered.5,6,9,10 In particular, treatment with valproic acid (VPA) in
combination with AEDs is associated with a high risk of fetal
MCM.11 The teratogenic effects of most AEDs appear to be dose
dependent,7,12 and numerous reports have conﬁrmed this dose
dependency in the case of VPA.7,9,10,13–15 Hence, transitioning from
VPA to another AED should be considered before conception, and
the lowest possible dose of the most appropriate AED should be
administered before conception in WWE.
The Japanese guidelines for the management of WWE, as
stipulated by the Societas Neurologica Japonica, recommend
preconception counseling to provide detailed information about
pregnancy and delivery in WWE and emphasize the importance of
the medication during pregnancy, along with antenatal manage-
ment involving the use of the lowest possible dose of the most
appropriate AED, avoiding VPA, possibly withdrawing AED before
conception, and supplementation with folic acid before and after
conception to prevent neural tube defects.16 International guide-
lines recommend monotherapy with lamotrigine owing to its low
risk of teratogenicity; however, this treatment option is currently
not permitted by the Japanese national health insurance policy.16
Although various guidelines recommend planned pregnancy for
WWE, the effects of planning remain largely unclear. Preconcep-
tion counseling for WWE has been reported to be effective for
reducing fetal MCM in children born to WWE receiving AEDs.17
However, the effects of a planned pregnancy on seizure control in
WWE during pregnancy and maternal and neonatal peripartum
outcomes have not been evaluated; in the present study, we aimed
to evaluate these effects. Moreover, we aimed to compare the
maternal and neonatal outcomes in planned and unplanned
pregnancies in WWE.
2. Methods
We retrospectively reviewed the hospital records of 153
pregnancies in WWE who were treated at the University of
Tsukuba Hospital (98 pregnancies) and Hokkaido University
Hospital (55 pregnancies) between 2003 and 2011. Planned
pregnancy was deﬁned as the completed process of planning
and preparing for pregnancy, during which the doses and numbers
of AEDs and maternal physical health prior to conception were
optimized by neurologists or neurosurgeons. According to the
Japanese Healthcare system, all WWE taking AEDs should be
followed up by their neurologists or neurosurgeons and not by
general physicians, even if their seizures are well controlled, and
some WWE who remain free of seizures without taking AEDs for a
long duration are normally not followed by any medical doctor.
Among WWE in the planned-pregnancy group, those who were
regularly reviewed by their neurologists or neurosurgeons before
conception received preconception counseling, epilepsy reassess-
ment, AED dose adjustment; after successful execution of the
planned pregnancy processes, their neurologists or neurosurgeons
considered their conception appropriate. For WWE in the planned-
pregnancy group who were not followed by medical doctors,
neurologists or neurosurgeons consulted their conception,
reviewed their condition, and considered pregnancy to be
appropriate. The unplanned-pregnancy group included all the
pregnancies not included in the planned-pregnancy group. WWE
in the unplanned pregnancy group who were regularly followed up
by their neurologists or neurosurgeons included those withunexpected pregnancies (for both WWE and medical doctors)
and those in whom the pregnancy had occurred during planning
but not when conception was considered appropriate by the
neurologists or neurosurgeons. The unplanned pregnancy group
also included pregnancies of WWE who were not followed up by
medical doctors and who did not consult neurologists or
neurosurgeons about their pregnancy before conception. The
planned pregnancy process was recorded on their medical chart or
the introduction form administered at our hospital. The pregnancy
was planned according to the discretion of the neurologist or
neurosurgeon and was not structured, but it was in accordance
with the guidelines for doctors authorized to treat patients under
the Japanese government medical insurance system, as well as
with the Japanese guidelines for the standard management of
epilepsy. Data regarding the history of preconception treatment
were unavailable in the case of 21 pregnancies, including medical
letters from neurologists or neurosurgeons and medical interview
forms; hence, these pregnancies were excluded from the study
analysis. We classiﬁed the remaining 132 pregnancies on the basis
of whether the pregnancy was planned or unplanned and
compared the seizure control in pregnancy and maternal and
neonatal outcomes in the 2 groups. Data were analyzed using the
Chi-square test or Fisher’s exact test and the Mann–Whitney U test,
as appropriate. A P value of <0.05 was considered statistically
signiﬁcant.
The approval of the institutional review board and ethics
committee was obtained at the University of Tsukuba Hospital
(number: H23-62) and Hokkaido University Hospital (number:
011-0133). Informed consent was obtained from all patients.
3. Results
The planned-pregnancy group consisted of 51 pregnancies
(39%), whereas the unplanned-pregnancy group comprised 81
pregnancies (61%).
3.1. Maternal backgrounds
Table 1 shows the patient demographics. Women in the
planned-pregnancy group were signiﬁcantly older (median age, 32
years; range, 17–42 years) than those in the unplanned-pregnancy
group (median age, 28 years; range, 22–38 years; P = 0.012)
(Table 1). The 2 groups showed no signiﬁcant difference with
respect to parity and gravidity (Table 1). Most women in both
groups were Japanese. None of the women in the 2 groups had
health conditions that were likely to affect maternal and neonatal
peripartum outcomes, such as diabetes mellitus, hypertension, and
hyperthyroidism. Only 1 woman in the unplanned-pregnancy
group had asthma, which was well controlled. None of the women
in the 2 groups had exposure to other teratogens except AEDs.
Eight women in each group were overweight (BMI > 25), and the
difference between the 2 groups in the proportion of overweight
patients was not statistically signiﬁcant (P = 0.32). Socio-economic
Table 3
Seizure control and AEDs during pregnancy.
Planned Unplanned P-Value
Epileptic seizure 8 (15.7%) 28 (34.6%) 0.018a
AEDs after seizure
Increased 6 20
Stable 2 7
Discontinued 0 1b
SUDEP 0 0 N.A.
Adjusted AEDs following pregnancy
diagnosis
0 (0.0%) 21 (25.9%) <0.001a
Switched 0 5
Decreased 0 5
Discontinued 0 11
AEDs discontinued by patients
themselvesc
3/39 (7.7%) 13/61 (21.3%) 0.07
Stable dose and drugs during
pregnancy
39 (76.5%) 48 (59.3%) 0.042a
a P < 0.05.
b A woman chose to discontinue AEDs against medical advice.
c Mothers not reaching AEDs were excluded, AED: antiepileptic drugs, SUDEP:
sudden unexpected death in epilepsy.
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different.
3.2. Treatment proﬁle for epilepsy
Table 2 shows the epileptic treatments administered to the
patients. Approximately 75% of WWE in both groups received
some kind of AED during pregnancy. Compared to the unplanned-
pregnancy group, the planned-pregnancy group showed a
signiﬁcantly higher proportion of WWE who received monother-
apy with AEDs (P = 0.049). For monotherapy, phenobarbital (PB)
was the most common medication used in the planned-pregnancy
group (10/31), followed by carbamazepine (CBZ) (8/31), VPA (8/
31), clonazepam (3/31), diazepam (1/31), and primidone (1/31). In
comparison, the primary drugs used for monotherapy in the
unplanned-pregnancy group were VPA (17/37), CBZ (10/37), PB (3/
37), phenytoin (PHT) (3/37), clonazepam (2/27), clobazam (1/37),
and zonisamide (1/37), in that order of frequency. Eight women
required polytherapy in the planned-pregnancy group, of which 1
took VPA. In the unplanned-pregnancy group, 24 women required
polytherapy, and 10 of them took VPA. VPA was required in
signiﬁcantly fewer cases in the planned-pregnancy group than in
the unplanned-pregnancy group (9 vs. 27, P = 0.031). No signiﬁcant
intergroup difference was noted with regard to folic acid
supplementation.
3.3. Seizure control and AEDs during pregnancy
A signiﬁcantly high rate of seizures during pregnancy was
recorded in the unplanned-pregnancy group than in the planned-
pregnancy group (Table 3). Due to concerns of teratogenicity,
changes in the AED schedule immediately after the diagnosis of
pregnancy were required in 21 WWE who belonged to the
unplanned-pregnancy group (Table 3). Of these 21 WWE, 8
requested the change themselves, whereas in 13 WWE, the change
was recommended by neurologists. Eleven women (52.4%) had
seizures even after altering the AED schedule. In particular, the rate
of seizures was high (66.7%) in 12 women who took VPA before
alteration of the AED schedule after pregnancy detection. With
regard to these 12 women, seizures were noted in 1 of 3 women for
whom VPA was switched to other AEDs, 1 woman whose VPA
dosage was reduced, and 6 of 8 women for whom VPA was
discontinued.
The rate of non-compliance with the AED treatment schedule
was higher in the unplanned-pregnancy group than in the
planned-pregnancy group (Table 3). In the planned-pregnancy
group, 3 women opted to discontinue AEDs before conception of
their own accord and then resumed these medications after
completion of the high-risk period of fetal malformations
according to the recommendations of their neurologists. They
did not experience any seizure during the AED-free period. In the
unplanned-pregnancy group, 13 women discontinued AEDs by
themselves after the detection of pregnancy. Eight of them
subsequently experienced seizures, which made it necessary to
restart AED treatment, but 1 WWE refused to resume the AED
treatment despite developing seizures. Of the remaining 5 womenTable 2
Treatment proﬁle for epilepsy.
Planned Unplanned P-Value
AED use 39 (76.5%) 61 (75.3%) 0.88
Monotherapya 31/39 (79.5%) 37/61 (60.7%) 0.049b
VPA includeda 9/39 (23.1%) 27/61 (44.3%) 0.031b
FA supplementation 23 (45.1%) 30 (37.0%) 0.36
a Mothers not receiving AEDs were excluded.
b P < 0.05, AED: antiepileptic drug, VPA: valproic acid, FA: folic acid.without seizures, 4 resumed AED treatment after the teratogenic
period, whereas 1 did not resume AED treatment throughout the
pregnancy, as per the advice of the neurologist.
The percentage of patients receiving stable antiepileptic
treatment, i.e. no change in the type and dosage of AEDs or no
additional requirement of AEDs, and was signiﬁcantly higher in the
planned-pregnancy group than in the unplanned-pregnancy group
(Table 3). In the planned-pregnancy group, 12 women required
medication adjustment, and all of them required an increase in the
dosage of AEDs because of seizures (6/12), abnormal electroen-
cephalogram ﬁndings (2/12), or for restarting previously with-
drawn AEDs after the organogenetic period (4/12). In comparison,
33 women in the unplanned-pregnancy group required alterations
in the AED schedule during pregnancy; the changes were required
because of pregnancy detection in 21 of these women and because
of seizures (increased dosage, 10 women) or for unknown reasons
(increased dosage, 2 women) in 12 of them.
3.4. Peripartum outcomes
Peripartum outcomes are shown in Table 4. There was no
signiﬁcant difference in the frequency of preterm birth between
the 2 groups (4/51 in planned vs. 8/81 in unplanned, P = 0.77).
Similarly, no signiﬁcant differences were noted in the frequency of
termination of pregnancy and the modes of delivery.
3.5. Neonatal outcomes
Table 5 shows the neonatal outcomes. There was no signiﬁcant
difference in the birth weight and Apgar scores of the live-born
neonates between the planned- and unplanned-pregnancy groups.
The rates of congenital malformations were nearly identical in the
2 groups. In the planned-pregnancy group, the congenital
malformations included 2 cases of ventricular septal defects
(VSDs), 1 case of cryptorchidism, and 1 case of congenital
diaphragmatic eventration. Exposure to AEDs in utero was noted
in 2 cases: one infant with VSD was exposed to VPA (600 mg) and
clonazepam (10 mg), whereas the one with cryptorchidism was
exposed to CBZ (400 mg). In the unplanned-pregnancy group, 6
neonates had congenital anomalies, with 1 case each of fetal
hydantoin syndrome (exposure to VPA [500 mg], PB [30 mg], and
PHT [100 mg]), stenosis of the external acoustic meatus (exposure
to VPA [800 mg] and PB [90 mg]), choroid plexus cyst (exposure to
PB [60 mg]), hypotonia with widely spaced nipples (exposure to
VPA [400 mg]), duodenal atresia with hypospadias (no AED
Table 4
Peripartum outcomes.
Planned Unplanned P-Value
Induced abortion 0 (0%) 4 (4.9%) 0.16
Spontaneous abortion 2 (3.9%) 5 (6.2%) 0.71
Stillbirth 0 (0%) 1 (1.2%) >0.99
Live birth 49 (96.1%) 71 (87.7%) 0.13
PIHa 2/49 (4.1%) 3/72 (4.2%) >0.99
NRFSa 7/49 (14.3%) 6/72 (8.3%) 0.3
FGRa 3/49 (6.1%) 4/72 (5.6%) >0.99
IUFDa 0/49 (0%) 1/72 (1.4%) >0.99
TOPb 9/49 (18.4%) 16/71 (22.5%) 0.58
Uncontrollable seizure 2 5
Obstetric indications 5c 8d
Elective 2 3
Cesarean deliveryb 16/49 (32.7%) 23/71 (32.4%) 0.98
Uncontrollable seizure 0 5
Obstetric indications 12e 12f
Cerebral AVM 3 3
Moyamoya disease 0 1
Elective 1 1
Others 0 1
Operative deliveryb 3/49 (6.1%) 1/71(1.4%) 0.30
Obstetric indications 3g 1h
Normal vaginal deliveryb 30/49 (61.2%) 47/71 (66.2%) 0.58
PIH: pregnancy-induced hypertension, NRFS: non-reassuring fetal status, FGR: fetal
growth restriction, IUFD: Intra-uterine fetal death, TOP: termination of pregnancy.
a Cases of abortion were excluded.
b Cases involving stillbirths and abortions were excluded.
c Four cases with NRFS and 1 case with FGR were included.
d Four cases with FGR, 3 cases with NRFS, and 1 case with PIH were included.
e Five cases with NRFS, 4 cases involving breech presentations, 1 case involving a
footling presentation, 1 case involving a low-lying placenta, and 1 case with prior
cesarean delivery were included.
f Three cases with NRFS, 2 cases involving breech presentations, 2 cases with
prior cesarean delivery, 2 cases with prior myomectomies, 1 case of placenta previa,
1 case of obstructed labor, and 1 cases involving a twin pregnancy were included.
g Two cases with NRFS and 1 case of obstructed labor were included.
h One case with NRFS was included.
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intergroup difference in the neonatal complications.
4. Discussion
In the present study, we investigated whether planned
pregnancy in WWE affected seizure control in pregnancy and
improved maternal and neonatal outcomes. We found that
planning a pregnancy with alterations in the treatment regimen
based on the currently accepted guidelines reduced the frequency
of seizures during pregnancy and fetal exposure to AEDs, but did
not signiﬁcantly improve the maternal or neonatal outcomes.
Compared to the unplanned-pregnancy group, the planned-
pregnancy group had a signiﬁcantly higher rate of monotherapy
and lower rate of VPA use, which reﬂects the clinical practice of the
treating neurologists in adjusting the lowest possible dose of theTable 5
Neonatal outcomes.
Planned 
Congenital malformationb 4/49 (8.2%) 
Birth weight (g)c 1467–3718 
Apgar score (1 min)c 1–10 
Apgar score (5 min)c 9–10 
Withdrawal syndromec 0/49 (0%) 
Neonatal hemorrhagec 0/49 (0%) 
NICU/GCU admissionc 8/49 (16.3%) 
a Four neonatal cases involving monochorionic, diamniotic twins were included.
b Cases involving abortions were excluded.
c Cases involving stillbirths and abortions were excluded, N.A.: not analyzed.most appropriate AED and switching from VPA to another AED
according to the currently followed guidelines. Furthermore,
compliance to medication was greater in the planned-pregnancy
group than in the unplanned-pregnancy group; this may be partly
attributed to the fact that the mothers were provided precise
information about the risks of AEDs for the fetus and the necessity
of taking AEDs to control seizure during the preconception
counseling. Three women in the planned-pregnancy group chose
to discontinue AEDs before conception, but restarted the AEDs
according to the advice of their neurologists. Thus, preconception
counseling and the active involvement of neurologists play
important roles in improving seizure control in WWE during
pregnancy.
In 21 cases in the unplanned-pregnancy group, the woman or
the neurologist attempted to change AEDs (5/21), decrease the
dose of AEDs (5/21), or discontinue the AEDs (11/21) immediately
after the detection of pregnancy because of concerns regarding the
teratogenicity of AEDs, which led to seizures in 11 cases (52.4%).
Seizures after changing the treatment schedule occurred particu-
larly in women who had been taking VPA (66.7%). These cases were
only observed in the unplanned-pregnancy group; it is possible
that the seizures would have been avoided and the fetal exposure
to AEDs would be minimized if the AEDs had been adjusted before
conception in a carefully planned manner. If these 11 women had
not had seizures, the rate of seizures during pregnancy in the
unplanned-pregnancy group would be reduced to 21.0%, which is
nearly equal to that in the planned-pregnancy group. Moreover,
the absence of preconception counseling may have led to the non-
compliance to AED intake noted in 13 women in the unplanned-
pregnancy group, 8 of whom experienced seizures (61.5%). The
non-compliance and subsequent occurrence of seizures may have
been prevented if these women had received appropriate
preconception counseling. We would like to emphasize that
adjusting medications for reducing teratogenicity of fetuses during
pregnancy poses a risk of inducing maternal epileptic seizures.
A decrease in the doses of AEDs during pregnancy was required
only in the unplanned-pregnancy group. Pregnancy may reduce
the plasma concentrations of AEDs,18 and therefore, any dose
adjustment that is required, usually involves increasing the
concentration of AEDs as the pregnancy progresses. Since this
may be counterintuitive to the natural physiology of pregnancy,
the neurologists may reduce the AED dose in an unplanned
pregnancy, as observed in 5 cases in this study. The occurrence of
pregnancy may have been so unexpected in these cases that the
doses of AEDs were decreased to reduce possibility of congenital
malformation of fetuses. These changes resulted in a high rate of
seizures, with 40% of these women subsequently experiencing
seizures. Although the exact reasons for decreasing the dose of
AEDs are unknown, we recommend a decrease in the dose before
conception in cases where pregnancy is planned.
There were several limitations to this study. We focused on
seizures during pregnancy, and the type of seizure and its directUnplanneda P value
6/74 (8.1%) >0.99
472–3985 0.66
3–10 0.58
6–10 0.11
2/73 (2.1%) 0.52
0/73 (0%) N.A.
16/73 (21.9%) 0.45
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this investigation. Nevertheless, we noted that epileptic seizures
warranted termination of pregnancy in 2 cases among the
planned-pregnancy group and in 5 cases in the unplanned-
pregnancy group. Furthermore, cesarean delivery was performed
in the unplanned-pregnancy group due to uncontrollable
seizures (Table 4). The unplanned-pregnancy group had a higher
rate of seizures during pregnancy and required more obstetric
interventions due to epileptic seizures than the planned-
pregnancy group. Thus, a planned pregnancy may result in
reduced seizure activity and consequently require fewer obstet-
ric interventions, such as termination of pregnancy or cesarean
delivery. This study is retrospective in nature, and the women
seeking preconceptional counseling are different from those with
unplanned pregnancies.
The primary objective of a planned pregnancy in WWE is to
avoid the use of AEDs, including VPA, which pose high teratogenic
risks. In the present study, although VPA could be avoided in a
signiﬁcantly greater proportion of women in the planned-
pregnancy group than in the unplanned-pregnancy group, the
rate of congenital malformations in the 2 groups was similar. This
may be explained by the following 2 possibilities. First, the other
AEDs are also teratogenic, and therefore, even if VPA is switched
with another AED, not all congenital malformations can be
prevented. A recent study on live-born infants revealed that
exposure to new-generation AEDs, such as lamotrigine, oxcarba-
zepine, topiramate, gabapentin, and levetiracetam, during the ﬁrst
trimester was not associated with an increased risk of major birth
defects.19 If older AEDs could be switched to newer AEDs before
conception in a planned pregnancy, then it may be possible to
decrease the risk of developing congenital malformations. Second,
our hospitals are general perinatal medical centers. Many fetuses
with congenital malformations diagnosed on antenatal ultraso-
nography are referred from nearby clinics and hospitals to our
centers, and incidental detection of epilepsy in such cases may
skew the results of this study. At our hospitals, the incidence of
MCM is 10.7% of all deliveries, which is much higher than the
incidence (1.6–2.2%)4–6 in the general population and also higher
than the percentage of fetuses exposed to AEDs (4.2–6.7%).4,5,7–9
Hence, this institutional bias limits our study ﬁndings on fetal
congenital malformations.
Although a greater proportion of WWE in the planned
pregnancy group received monotherapy of AEDs and required
less VPA than the unplanned pregnancy group, possibly because of
the adjustments made to AED dosage by neurologists or
neurosurgeons, folate prescription levels were the same in the 2
groups. The situation on the supplementation of folic acid for
women of the reproductive age in Japan may be related to these
results. Folic acid intake from the Japanese diet is appropriate and
neural tube defects in Japan are less frequent than that in the other
countries.20 Therefore, the awareness of folic acid supplementation
for women of reproductive age among medical doctors, even
among the obstetricians, are lower in Japan than that in countries
in Europe or Oceania as well as in other Asian countries, such as
Korea or Taiwan, despite promotion by Japanese Ministry of
Health, Labour and Welfare.21 Because of these factors, neurolo-
gists or neurosurgeons may be less aware of folic acid supplemen-
tation for WWE in the planned pregnancy process, which may
inﬂuence the results. Furthermore, we analyzed only WWE
receiving folate prescription of 5 mg/day in the present study,and not WWE receiving over-the-counter drugs of folate supple-
mentation (0.4 mg/day), which may also inﬂuence our results.
5. Conclusions
In WWE, planned pregnancy is associated with good seizure
control during pregnancy and less fetal exposure to AEDs. In cases
of unplanned pregnancy, the doses of AEDs are adjusted
immediately after pregnancy is determined, which results in a
higher rate of seizures during pregnancy. Although we noted that
planned pregnancy may also improve maternal and neonatal
peripartum outcomes, we were unable to conﬁrm this ﬁnding in
the present study.
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